Literature DB >> 803527

An in vitro method for study of human lymphocyte cytotoxicity against mumps-virus-infected target cells.

T Andersson, V Stejskal, B Harfast.   

Abstract

A chromium release assay was used to study lymphocyte-mediated cytotoxicity against mumps virus-infected target cells in vitro. Purified lmyphocytes from randomly selected donors killed significantly more virus-infected Vero cells than non-infected cells. Lymphocyte-target cell ratios of 50 to 100:1 and incubation period from 16 to 20 hr were optimal for determination of cytotoxicity. The lymphocyte induced chromium release was not obviously correlated with serum mumps hemagglutination-inhibition titers of the effector cell donors. However, the lymphocyte reaction against virus-infected target cells seems to have an immunologic basis. Thus, the more pronounced susceptibility of mumps-infected target cells as compared to non-infected cells was not due to a cytocidal effect of the virus, since spontaneous isotope release from both target cells was the same. Also, cord blood lymphocytes which had exhibited good cytotoxicity when induced either with phytohemagglutinin or with antiserum against target cell antigens were not cytotoxic for mumps-infected Vero cells. Moreover, the lymphocyte reaction against virus infected target cells could be inhibited by high concentrations of hyperimmune rabbit antimumps sera. On the other hand, lower concentrations of antisera specifically poteniated the lymphoycte-mediated isotope release from mumps-infected target cells.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 803527

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  22 in total

1.  Immunologic defense in bacterial and viral meningitis in children.

Authors:  J Ströder; R Seger
Journal:  Eur J Pediatr       Date:  1976-12-09       Impact factor: 3.183

2.  Demonstration of T-cell and K-cell cytotoxicity against measles-infected cells in normal subjects, multiple sclerosis and subacute sclerosing panencephalitis.

Authors:  P W Ewan; P J Lachmann
Journal:  Clin Exp Immunol       Date:  1977-10       Impact factor: 4.330

3.  Immune response in humans after vaccination with vaccinia virus: generation of a virus-specific cytotoxic activity by human peripheral lymphocytes.

Authors:  L H Perrin; R M Zinkernagel; M B Oldstone
Journal:  J Exp Med       Date:  1977-10-01       Impact factor: 14.307

4.  Increased sensitivity to natural killing in Raji cells is due to effector recognition of molecules appearing on target cell membranes following EBV cycle induction.

Authors:  B A Blazar; J Fitzgerald; L Sutton; M Strome
Journal:  Clin Exp Immunol       Date:  1983-10       Impact factor: 4.330

5.  T-cell-mediated cytotoxic response to mumps virus in humans.

Authors:  H Tsutsumi; Y Chiba; W Abo; S Chiba; T Nakao
Journal:  Infect Immun       Date:  1980-10       Impact factor: 3.441

6.  The effects of prednisolone in leucocyte function in man. A double blind controlled study.

Authors:  J R Clarke; R F Gagnon; F M Gotch; M R Heyworth; I C Maclennan; S C Truelove; C A Waller
Journal:  Clin Exp Immunol       Date:  1977-05       Impact factor: 4.330

7.  Humoral and cell-mediated immune responses in humans before and after revaccination with vaccinia virus.

Authors:  A Møller-Larsen; S Haahr
Journal:  Infect Immun       Date:  1978-01       Impact factor: 3.441

8.  Cell-mediated cytotoxicity to herpes-infected cells in humans: dependence on antibodies.

Authors:  A Moller-Larsen; I Heron; S Haahr
Journal:  Infect Immun       Date:  1977-04       Impact factor: 3.441

9.  Specific immune lysis of paramyxovirus-infected cells by H-2-compatible thymus-derived lymphocytes.

Authors:  P C Doherty; R M Zinkernagel
Journal:  Immunology       Date:  1976-07       Impact factor: 7.397

10.  Syncytia inhibition by immune lymphocytes: in vitro test for immunity to canine distemper.

Authors:  S Krakowka; A L Wallace; A Koestner
Journal:  J Clin Microbiol       Date:  1978-03       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.